Table 2.
Ongoing clinical trials of immunotherapy combined with local therapy in the late-line treatment of pMMR/MSS mCRC registered on clinicaltrials.gov.
| Study name/ID | Intervention | Target | CRC study population | Phase | Status |
|---|---|---|---|---|---|
| NCT04535024 | SABR + Sintilimab | PD-1; Ablation | MSS Oligometastatic CRC | II | Recruiting |
| NCT04030260 | Regorafenib + PD-1 antibody + Radiotherapy ± SABT | PD-1; VEGFR; Radiotherapy | MSS Metastatic CRC | II | Recruiting |
| NCT04575922 | ipilimumab + nivolumab, +Radiation therapy | PD-1; CTLA-4; Radiotherapy | Metastatic MSS CRC | II | Active, not recruiting |
| NCT03104439 | Nivolumab + Ipilimumab + Radiation Therapy | PD-1; CTLA-4; Radiotherapy | MSS and MSI High CRC | II | Recruiting |
| NCT05292417 | Sintilimab + GM-CSF + Fruquintinib + Radiotherapy | PD-1; VEGFR; Radiotherapy | MSS Metastatic CRC | II | Recruiting |
| NCT05160727 | Tislelizumab + Irinotecan + Radiotherapy | PD-1; Radiotherapy; Chemotherapy | MSS inoperable recurrent and metastatic CRC | II | Recruiting |
| NCT04659382 | SIRT + Xelox + Bevacizumab + Atezolizumab | PD-1; VEGFR; Radiotherapy; Chemotherapy; | MSS mCRC with predominantly non-operable liver metastases | II | Recruiting |
| NCT04108481 | Yttrium-90 radioembolization (Y90-RE) + durvalumab | PD-1; Radiotherapy; | liver-predominant, MSS Metastatic CRC | I/II | Suspended (Working on revisions) |
| NCT03802747 | Durvalumab/Durvalumab and Tremelimumab + SIRT/SBRT | PD-1; CTLA-4; Radiotherapy | liver metastases for patients with MSS CRC | I | Withdrawn (PI left the institution) |
| NCT05438108 | SBRT + CapeOX + Bevacizumab + Sintilimab | PD-1; VEGFR; Radiotherapy; Chemotherapy; | MSS Metastatic CRC | II | Recruiting |
| NCT02437071 | Pembrolizumab + Radiotherapy/Ablation | PD-1; Radiotherapy; Ablation | Metastatic CRC | II | Active, not recruiting |
| NCT04924179 | Fruquintinib + Tislelizumab + SBRT | PD-1; VEGFR; Radiotherapy; | Metastatic CRC | II | Active, not recruiting |
| NCT05635149 | Fruquintinib + PD-1 antibody + CRT/SBRT | PD-1; VEGFR; Radiotherapy; | MSS Metastatic CRC | Observational Cohort Study | Recruiting |
| NCT02888743 | Durvalumab + Tremelimumab + High or low dose RT | PD-1; CTLA-4; Radiotherapy | MSS Metastatic CRC | II | Active, not recruiting |
| NCT05894837 | Serplulimab + Regorafenib + Hepatic Artery Bicarbonate Infusion | PD-1; Chemotherapy; Hepatic Artery Bicarbonate Infusion | Metastatic CRC liver Metastases | II | Active, not recruiting |
*Radiation Therapy (RT); Stereotactic Body Radiation Therapy (SBRT); Selective Internal Radiation Therapy (SIRT); Stereotactic Ablative Radiotherapy (SABR); Conventional radiotherapy (CRT).